Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 17;11:18534. doi: 10.1038/s41598-021-97753-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Expression of CD14 and CD209 during dendritic cell differentiation in the presence and absence of EV. CD14 expression following treatment with FaDu cell line EVs: (A) There were no significant differences in the percentage of iDCs expressing CD14 between control (16.2% ± 1.8%) and EV treated cells (17.1 ± 5.3% and 17.9 ± 5.5%); (B) there were significant differences in the mean intensity of fluorescence (MFI) of CD14 in iDCs between the control (2884 ± 1857) and EV treated samples (5636 ± 1613 and 7605 ± 3265) depending of EV concentration. CD14 expression following treatment with SCC25 cell line EVs: (C) There were significant differences in the percentage of iDCs expressing CD14 between the control (15.5 ± 1.3%) and EV treated cells (24.0 ± 2.3% and 33.5 ± 0.3%) depending on EV concentration; (D) there were significant differences in CD14 MFI between control (2402 ± 253) and EV treated cells (3275 ± 170 and 3623 + 111) depending on EV concentration; (E) Representative dot plots displaying iDCs expressing CD14 on day 6 of culture without treatment (CTRL) and EV-treated cells. CD209 expression following treatment with FaDu cell line EVs: (F) There were significant differences in the percentage of iDCs expressing CD209 between control (87.4 ± 3.8%) and EV treated cells (42.8 ± 10.2% and 40.5 ± 7.1%); (G) there were differences between untreated iDCs MFI (36,670 ± 802) and treated iDCs (11,543 + 4719 and 9900 ± 2034). CD209 expression following treatment with SCC25 cell line EVs: (H) there were significant differences in iDCs expressing CD209, between the control (96.5 ± 2.1%) and treated cells (92 ± 4.8% and 87.9 ± 1.9%), depending on EV concentration; (I) there were differences between untreated iDCs MFI (62,514 + 12,407) and treated cells (49,110 ± 5632 and 42,011 ± 1568) (n = 4); (J) Representative dot plot graphs displaying iDCs expressing CD209 on day 6 of culture without treatment (CTRL) and EV-treated cells with different concentrations of EVs. Representative results of n = 4 samples per lineage type. The statistical analysis was performed using one way ANOVA with Dunnett correction.